RxSight, Inc.

RXST · NasdaqGM · Stock · Healthcare
$4.68
+3.54% today
Delayed price,

What RxSight does

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Key facts

Sector
Healthcare
Industry
Medical Devices
Market cap
$194.7M
P/E (ttm)
—
Forward P/E
-6.8
Dividend yield
0.00%
Beta
1.14
Profit margin
-36.8%
Employees
461
Headquarters
Aliso Viejo, CA, United States
Exchange
NasdaqGM

Performance

1 Month
-10.0%
3 Months
-15.7%
6 Months
-38.5%
1 Year
-43.2%
5 Years
-56.9%
$4.4052-week range$13.22
Biggest setback — last 12 months
-64.2%
1 Dec 2025 → 12 Oct 2026
Fell from $12.63 to $4.52 — its sharpest sustained decline this year.
Biggest run-up — last 12 months
+53.3%
13 Oct 2025 → 1 Dec 2025
Ran from $8.24 to $12.63 — its strongest sustained advance this year.

Price outlook — trend & volatility model

▼ Trend: Downtrend
Price is below its 20-, 50- and 200-day averages, each stacked below the next — a classic technical downtrend structure.
HorizonBear case (−1σ)Base caseBull case (+1σ)
1 Month$3.94 (-15.8%)$4.68$5.56 (+18.8%)
3 Months$3.47 (-25.8%)$4.68$6.31 (+34.8%)
6 Months$3.07 (-34.4%)$4.68$7.14 (+52.5%)
12 Months$2.58 (-45.0%)$4.68$8.50 (+81.7%)
Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 59.7%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Recent headlines

Recent insider activity

Acquired 517,540 shares — Wilterding Mark, Chief Financial Officer · 2026-09-09
Acquired 783,712 shares — Weinberg Eric, See remarks · 2026-09-09
Acquired 1,589,266 shares — Kurtz Ronald M MD, Chief Medical Officer · 2026-09-09
Acquired 849,599 shares — Goldshleger Ilya, Chief Operating Officer · 2026-09-09
Sold 18,525 shares at $6.96 — Kurtz Ronald M MD, Chief Medical Officer · 2026-09-02
Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.